Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has provided an announcement.
Botanix Pharmaceuticals has called a general meeting of shareholders for 1 April 2026 in Perth, advising investors that meeting materials will be provided electronically unless hard copies have been specifically requested. The board is urging shareholders to lodge directed proxy forms ahead of the deadline on 30 March to ensure their votes are counted.
The meeting will consider a set of interdependent resolutions tied to a capital raising announced in February 2026, including the second tranche of a placement, a security purchase plan and related option issues. The company warns that if these resolutions fail, it will forfeit access to further funds beyond about A$14.9 million already raised, potentially leaving it without sufficient capital for its planned activities and exposing shareholders to solvency and additional financing risks.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals is an Australian-listed biotechnology company focused on developing pharmaceutical products. It operates in the life sciences sector and relies on capital raisings to fund its proposed development activities and ongoing operations.
Average Trading Volume: 8,313,114
Technical Sentiment Signal: Sell
Current Market Cap: A$124.2M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.